Page last updated: 2024-12-05

methionine sulfoximine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Methionine sulfoximine (MSO) is a potent inhibitor of glutamine synthetase, a key enzyme in the biosynthesis of glutamine. It acts by mimicking the substrate methionine and binding to the active site of the enzyme. MSO is a powerful tool for studying the role of glutamine synthetase in various biological processes, including neurotransmission, cell proliferation, and nitrogen metabolism. It has also been explored as a potential therapeutic agent for certain neurological disorders, such as epilepsy. MSO is typically synthesized by reacting methionine with sulfamic acid under acidic conditions. Its effects on glutamine synthetase have been extensively studied, leading to insights into the regulation of glutamine metabolism and its implications for cellular function. Research on MSO has also shed light on the mechanisms underlying the pathogenesis of certain neurological disorders and the potential for therapeutic interventions targeting glutamine synthetase.'

methionine sulfoximine : A non-proteinogenic alpha-amino acid that is the sulfoximine derivative of methionine . [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

L-methionine sulfoximine : A methionine sulfoximine in which the amino group has S-stereochemistry. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16118
CHEMBL ID1615096
CHEBI ID47833
SCHEMBL ID187873
MeSH IDM0013579
PubMed CID89034
CHEMBL ID143324
CHEMBL ID1627202
CHEBI ID28490
SCHEMBL ID187872
MeSH IDM0013579

Synonyms (124)

Synonym
dl-(3-amino-3-carboxypropyl) methyl sulfoximine
BB 0260911
methionine sulfoximine
nsc49169
nsc-49169
SR-01000632335-1
2-amino-4-(s-methylsulphonimidoyl)butyric acid
2-amino-4-(s-methylsulfonimidoyl)butanoic acid
1982-67-8
CHEBI:47833 ,
methionine-rs-sulfoximine, l-
ai3-62723
butanoic acid, 2-amino-4-(s-methylsulfonimidoyl)-
sulfoximine, s-(3-amino-3-carboxypropyl)-s-methyl-, dl-
einecs 217-845-8
methionine-dl-sulfoximine, dl-
ccris 5096
STK501262
dl-methionine sulfoximine
l -s-(3-amino-3-carboxypropyl)-s-methylsulfoximine
2-amino-4-(methylsulfonimidoyl)butanoic acid
FT-0694474
dl-methionine-dl-sulfoximine
CHEMBL1615096
CCG-42326
AKOS005171800
FT-0671137
FT-0671138
FT-0627959
SCHEMBL187873
W-109734
dl-banthionine-dl-sulfoximine
mfcd00063094
J-014271
s-(3-amino-3-carboxypropyl)-s-methyl-dl-sulfoximine
s-(3-amino-3-carboxypropyl)-s-methylsulfoximine, 9ci
butanoic acid, 2-amino-4-(s-methylsulfonimidoyl)- (9ci)
2-amino-4-(s-methylsulfonimidoyl)-butanoic acid
dl-methionine dl-sulfoximine
l-methionine-rs-sulfoximine
SXTAYKAGBXMACB-UHFFFAOYSA-N
Q27120816
l-methionine-dl-sulfoximine
AE-641/01924064
SB33993
DTXSID201031266
CS-0449453
EN300-373833
2-amino-4-[imino(methyl)oxo-lambda6-sulfanyl]butanoic acid
(r)-l-s-(3-amino-3-carboxypropyl)-s-methylsulfoximine
2-amino-4-(s-methylsulfonimidoyl)butanoicacid
PRESTWICK3_000523
MSO ,
BPBIO1_000557
EU-0100797
PRESTWICK_805
methionine sulfoximine (l)
LOPAC0_000797
PRESTWICK2_000523
BSPBIO_000505
AB00513853
15985-39-4
C03510
(2s)-2-amino-4-(s-methylsufonimidoyl)-butanoic acid
l-methionine sulfoximine
(2s)-2-amino-4-(s-methylsulfonimidoyl)butanoic acid
CHEBI:28490 ,
SPBIO_002426
PRESTWICK0_000523
PRESTWICK1_000523
NCGC00094132-03
NCGC00094132-01
NCGC00094132-02
M 5379
l-s-(3-amino-3-carboxypropyl)-s-methylsulfoximine
NCGC00094132-04
CHEMBL143324
HMS1569J07
A810076
l-methionine-sulfoximine
CHEMBL1627202
HMS3262O16
HMS2096J07
CCG-204881
unii-m9p6yz6jx9
butanoic acid, 2-amino-4-(s-methylsufonimidoyl)-, (2s)-
l-methionine-s,r-sulfoximine
(2s)-2-amino-4-(s-methylsufonimidoyl)butanoic acid
m9p6yz6jx9 ,
LP00797
mfcd00002621
AKOS015892783
SCHEMBL187872
butanoic acid, 2-amino-4-(s-methylsulfonimidoyl)-, (2s)-
methionine-dl-sulfoximine, l-
methionine-dl-sulfoximine
NCGC00261482-01
tox21_500797
l-methionine [r,s]-sulfoximine
l-methionine sulfoximine, certified reference material, tracecert(r)
J-009648
SR-01000075995-1
sr-01000075995
DB14103
AS-40141
DTXSID30936181
Q27103738
BCP10104
SDCCGSBI-0050774.P002
NCGC00094132-07
l-methionine-(s,r)-sulfoximine
2s-amino-4-(s-methylsulfonimidoyl)-butanoic acid
butanoic acid, 2-amino-4-((s(s))-s-methylsulfonimidoyl)-, (2s)-
de3d2pz3tt ,
(2s)-2-amino-4-((s(s))-s-methylsulfonimidoyl)butanoic acid
methionine sulfoximine, (s)-
unii-de3d2pz3tt
(2s)-2-amino-4-[imino(methyl)oxo-|e?-sulfanyl]butanoic acid
butanoic acid, 2-amino-4-((s(r))-s-methylsulfonimidoyl)-, (2s)-
(2s)-2-amino-4-((s(r))-s-methylsulfonimidoyl)butanoic acid
(2s,sr)-methionine sulfoximine
l-methionine-(r)-sulfoximine
CS-0013677
HY-B1692

Research Excerpts

Overview

Methionine sulfoximine is a xenobiotic amino acid derived from methionine. It is a centrally acting neurotoxin which inhibits the glutamate metabolism enzymes and has convulsive properties.

ExcerptReferenceRelevance
"Methionine sulfoximine (MSO) is a well-established inhibitor for the archetypal glutamine synthetase (GS) but inhibitors for most GS-like enzymes are unknown."( Mechanism-Based Design of the First GlnA4-Specific Inhibitors.
Funk, J; Hausch, F; Krysenko, S; Meyners, C; Purder, PL; Wohlleben, W, 2022
)
1.44
"Methionine sulfoximine (MSO) is a rare amino acid. "( Methionine sulfoximine shows excitotoxic actions in rat cortical slices.
Bains, JS; Curry, K; Pasqualotto, BA; Shaw, CA, 1999
)
3.19
"Methionine sulfoximine is a xenobiotic amino acid derived from methionine. "( The xenobiotic methionine sulfoximine modulates carbohydrate anabolism and related genes expression in rodent brain.
Ardourel, MY; Cloix, JF; Hélary-Bernard, K; Hevor, T, 2000
)
2.1
"L-Methionine sulfoximine is a substrate of L-amino acid oxidase (Crotalus adamanteus), glutamine transaminase, and gamma-cystathionase. "( Enzymatic reactions of methionine sulfoximine. Conversion to the corresponding alpha-imino and alpha-keto acids and to alpha-ketobutyrate and methane sulfinimide.
Cooper, AJ; Meister, A; Stephani, RA, 1976
)
1.29
"Methionine sulfoximine (MSO) is a centrally acting neurotoxin which inhibits the glutamate metabolism enzymes and has convulsive properties. "( Long-term effects of the administration of the convulsive substance DL-methionine-DL-sulfoximine to the rabbit.
Anogianakis, G; Apostolakis, M; Economou, L; Kallaras, C; Liangouris, J; Nowack-Apostolaki, E; Zaraboukas, T, 1989
)
1.72

Actions

ExcerptReferenceRelevance
"Methionine sulfoximine does not inhibit ammonia transport in R."( Role of metabolism in the chemotactic response of Rhodobacter sphaeroides to ammonia.
Armitage, JP; Poole, PS, 1989
)
1

Treatment

Pretreatment with methionine sulfoximine attenuated the decrease in cytoplasmic density and the increase in nuclear circumference. Most perivascular endfeet remained as dense as occurred with sodium acetate infusion.

ExcerptReferenceRelevance
"Pretreatment with methionine sulfoximine, but not buthionine sulfoximine, attenuated the decrease in cytoplasmic density and the increase in nuclear circumference; most perivascular endfeet remained as dense as occurred with sodium acetate infusion."( Inhibition of glutamine synthetase reduces ammonia-induced astrocyte swelling in rat.
Brusilow, SW; Cork, LC; Hirata, T; Koehler, RC; Takahashi, H; Traystman, RJ; Willard-Mack, CL, 1996
)
0.62
"Pretreatment with methionine sulfoximine inhibited glutamine synthetase, prevented the increase in glutamine during hyperammonemia, and prevented the decrease in specific gravity."( Glutamine synthetase inhibition prevents cerebral oedema during hyperammonemia.
Brusilow, SW; Koehler, RC; Takahashi, H; Traystman, RJ, 1990
)
0.6

Toxicity

ExcerptReferenceRelevance
" Comparison of the tested compounds showed that the structural requirements for toxic potency was a phenolic ring having an allyl substituent at the 4-position."( Hepatotoxicity of eugenol and related compounds in mice depleted of glutathione: structural requirements for toxic potency.
Mizutani, T; Nomura, H; Satoh, K, 1991
)
0.28
" Intraperitoneal injection of Cr(VI) did not inhibit hepatic glutathione reductase activity, even at toxic doses."( Possible role of glutathione in chromium(VI) metabolism and toxicity in rats.
Standeven, AM; Wetterhahn, KE, 1991
)
0.28
" Sera from both rats and monkeys following gavage with acetaminophen were also toxic to cultured embryos."( Acetaminophen toxicity to cultured rat embryos.
Bruno, M; Gamache, P; Hinson, JA; Khairallah, E; Klein, NW; Weeks, BS, 1990
)
0.28
"The rationale for melanoma specific dihydroxybenzene containing antitumor agents is based in part upon the ability of the enzyme tyrosinase to oxidize these pro drugs to toxic intermediates."( Effects of tyrosinase activity on the cytotoxicity of 3,4-dihydroxybenzylamine and buthionine sulfoximine in human melanoma cells.
Fitzgerald, GB; Prezioso, JA; Wick, MM,
)
0.13
" These data suggest that the nephrotoxicity of PAP may be due in part to the formation of a proximate toxic metabolite in the liver which is excreted in the bile, subsequently reabsorbed and transported via the systemic circulation to the kidney where the toxic effects occur."( Effects of biliary cannulation and buthionine sulphoximine pretreatment on the nephrotoxicity of para-aminophenol in the Fischer 344 rat.
Bonner, FW; Eason, CT; Gartland, KP; Nicholson, JK, 1990
)
0.28
" That administration of glutathione has a protective effect on cisplatin toxicity suggests that the toxic effects of cisplatin may be exerted both intracellularly and extracellularly, and that extracellular glutathione (or its degradation products) may form a complex with cisplatin extracellularly."( Protection against cisplatin toxicity by administration of glutathione ester.
Anderson, ME; Meister, A; Naganuma, A, 1990
)
0.28
" The production of a toxic metabolite in the livers of glutathione-depleted mice that is circulated to susceptible renal cells may be the mechanism of this interesting organ-selective shift in toxicity of 3MI."( Organ-selective switching of 3-methylindole toxicity by glutathione depletion.
Kuntz, DJ; McGill, LD; Yost, GS, 1990
)
0.28
" Since diet and many drugs (including cyclophosphamide itself) are known to affect glutathione levels, the present studies suggest that cardiac and skeletal muscle glutathione content is likely to be a clinically significant determinant of the frequency and severity of the adverse drug interactions and systemic toxicity sometimes observed during cyclophosphamide therapy."( Glutathione protects cardiac and skeletal muscle from cyclophosphamide-induced toxicity.
Aisaka, K; Bossen, EH; Colvin, OM; Friedman, HS; Gross, SS; Hilton, J; Levi, R; Popp, J; Powell, JB; Reimer, KA, 1990
)
0.28
" Administration of a toxic dose of precocene II (175 mg/kg) to male Sprague-Dawley rats rapidly depleted hepatic GSH, produced histopathological changes in the liver, and induced increases in serum aminotransferase activity."( Alteration of precocene II-induced hepatotoxicity by modulation of hepatic glutathione levels.
Duddy, SK; Hsia, MT, 1989
)
0.28
" INO was very toxic towards HT-29 cells and was equally toxic under aerobic and hypoxic conditions."( Cytotoxicity and glutathione depletion by 1-methyl-2-nitrosoimidazole in human colon cancer cells.
Gipp, JJ; McClelland, RA; Mulcahy, RT; Panicucci, R; Ublacker, GA, 1989
)
0.28
"2) that decreases cellular levels of glutathione markedly] were sensitized to the toxic effects of CdCl2."( Glutathione, a first line of defense against cadmium toxicity.
Anderson, ME; Meister, A; Singhal, RK, 1987
)
0.27
" Basic amino acids (except histidine) were less effective in protecting embryos: Glutamine and lysine reduced the toxic effect only slightly, and arginine had no effect."( Enhancement of methylmercury toxicity by L-cystine in cultured mouse blastocysts.
Matsumoto, N; Spindle, A,
)
0.13
" Thus the toxic effects after acute GSH depletion to approximately equal to 5% of control by BSO plus dimethylfumarate (DMF) were evaluated in these same 66 cells to determine if this anti-proliferative effect could be minimized."( Toxic effects of acute glutathione depletion by buthionine sulfoximine and dimethylfumarate on murine mammary carcinoma cells.
Biaglow, JE; Dethlefsen, LA; Lehman, CM; Peck, VM, 1988
)
0.27
" Yet neither substance protected mice from the toxic effects of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on dopaminergic nigrostriatal neurons, as shown by marked depletion of striatal dopamine content when animals were sacrificed."( Manipulation of glutathione contents fails to alter dopaminergic nigrostriatal neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse.
Jones, K; Perry, TL; Wright, JM; Yong, VW, 1986
)
0.27
" Although these derivatives did not display selective toxicity toward the hypoxic cells, they were significantly more toxic than 6-TC to this cell line at 500 microM after a 2-h exposure."( Modification of antitumor disulfide cytotoxicity by glutathione depletion in murine cells.
Kirkpatrick, DL, 1987
)
0.27
" In contrast, pretreatment with cysteine (100-200 mg/kg) inhibited the elevation of serum enzyme activities at a toxic dose of BHT (1000 mg/kg)."( Effects of buthionine sulfoximine and cysteine on the hepatotoxicity of butylated hydroxytoluene in rats.
Nakagawa, Y, 1987
)
0.27
"Previous data have demonstrated that methyl chloride (MeCl) is toxic to B6C3F1 mice under both acute and chronic exposure conditions, and that conjugation of MeCl with glutathione (GSH) is a key step in the metabolism of MeCl."( Inhibition of the acute toxicity of methyl chloride in male B6C3F1 mice by glutathione depletion.
Bus, JS; Chellman, GJ; Norton, RM; White, RD, 1986
)
0.27
" These structural requirements essentially are the same as those for the toxic potency in the lung (T."( Hepatotoxicity of butylated hydroxytoluene and its analogs in mice depleted of hepatic glutathione.
Fujita, S; Mizutani, T; Nakanishi, K; Nomura, H, 1987
)
0.27
" The mechanisms responsible for the disparate toxic outcomes for these closely related structural isomers are not fully understood."( Naphthylisothiocyanate disposition in bile and its relationship to liver glutathione and toxicity.
Jean, PA; Roth, RA, 1995
)
0.29
" Studies have shown that the formation of toxic metabolites can result from glutathione (GSH) conjugation of toxicants in the liver."( Profile of procarbazine-induced embryotoxicity in an embryo hepatocyte co-culture system and after in utero glutathione depletion.
Andrews, JE; Ebron-McCoy, MT; Kavlock, RJ; Nichols, HP, 1995
)
0.29
" Two groups could be distinguished: PMA, EMT and MMC are one order of magnitude more toxic than MC, MN and MA."( Cytotoxicity of mercury compounds in LLC-PK1, MDCK and human proximal tubular cells.
Bohets, HH; D'Haese, PC; De Broe, ME; Dierickx, PJ; Nouwen, EJ; Van der Biest, I; Van Landeghem, GF; Van Thielen, MN, 1995
)
0.29
" Among related amino acids, DL-alpha-aminoadipic acid (DL-alpha-AAA), which is well known as a selective gliotoxin in the retina, is also toxic to these cells."( Cystine/glutamate antiporter expression in retinal Müller glial cells: implications for DL-alpha-aminoadipate toxicity.
Ishita, S; Kato, S; Mawatari, K; Sugawara, K, 1993
)
0.29
" These results suggest that acrolein and 4HPC are equipotent cytotoxins and that a transient depletion in GSH accompanies this toxic effect in cardiac myocytes."( Effect of sulfhydryl compounds and glutathione depletion on rat heart myocyte toxicity induced by 4-hydroperoxycyclophosphamide and acrolein in vitro.
Dorr, RT; Lagel, K, 1994
)
0.29
" Hepa 1c1c-9 cells were exposed to varying concentrations of several reactive metabolites implicated in adverse drug reactions and the toxicity of the compounds assessed using applied fluorescence technology."( A comparative study of the toxicity of chemically reactive xenobiotics towards adherent cell cultures: selective attenuation of menadione toxicity by buthionine sulphoximine pretreatment.
Leeder, JS; Riley, RJ; Spielberg, SP, 1993
)
0.29
"Glutathione (GSH) and glutathione S-transferases (GSTs) play an important role in the protection of cells against toxic effects of many electrophilic drugs and chemicals."( Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells.
Chen, G; Waxman, DJ, 1994
)
0.29
" The toxic effects, GSH depletion and radiosensitivity of BSO on retinoblastoma cells are reported in this paper."( The toxic effects, GSH depletion and radiosensitivity by BSO on retinoblastoma.
Ding, L; Jin, Y; Ni, C; Wang, W; Yi, X, 1994
)
0.29
" Precocene II was also toxic to 72-h cultures, although the effect of the serum-free medium was attenuated."( Toxicity of precocene II in rat hepatocyte cultures: effects of serum and culture time.
Fry, JR; Hammond, AH, 1994
)
0.29
" We have investigated whether these toxic effects of arsenite and the cellular arsenic content are also modulated by the intracellular GSH."( Glutathione as a cellular defence against arsenite toxicity in cultured Chinese hamster ovary cells.
Huang, CF; Huang, H; Jan, KY; Jinn, CM; Wu, DR, 1993
)
0.29
" While exogenous PpIX was more toxic than hemin in both cell lines, this toxicity was not due to iron depletion following intracellular heme formation since ferric citrate did not reverse PpIX toxicity."( Hemin toxicity in a human epithelioid sarcoma cell line.
Braverman, S; Helson, C; Helson, L,
)
0.13
" Azathioprine and monocrotaline were found to be selectively more toxic to SEC than to hepatocytes."( Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venoocclusive disease.
DeLeve, LD; Kaplowitz, N; Kuhlenkamp, JF; Wang, X, 1996
)
0.29
" In accordance with previous studies with the rat, p-methoxythiobenzamide was more toxic than thiobenzamide, and conversely p-chlorothiobenzamide was markedly less toxic as assessed by serum alanine aminotransferase (ALT) activity."( Relative hepatotoxicity of 2-(substituted phenyl)thiazoles and substituted thiobenzamides in mice: evidence for the involvement of thiobenzamides as ring cleavage metabolites in the hepatotoxicity of 2-phenylthiazoles.
Mizutani, T; Suzuki, K, 1996
)
0.29

Pharmacokinetics

ExcerptReferenceRelevance
" Diethylmaleate pretreatment decreased the total clearance and increased the half-life of acetaminophen."( Role of glutathione turnover in drug sulfation: differential effects of diethylmaleate and buthionine sulfoximine on the pharmacokinetics of acetaminophen in the rat.
Galinsky, RE, 1986
)
0.27
"The development of time-dependent pharmacodynamic models in cancer chemotherapy has been extremely limited."( Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Brennan, J; Gallo, JM; Halbherr, T; Hamilton, TC; Laub, PB; O'Dwyer, PJ; Ozols, RF, 1995
)
0.29
" Values for steady-state volume of distribution and renal clearance were similar for both isomers, but total clearance, nonrenal clearance, and half-life were approximately 25% different, with the R-(inactive) isomer being eliminated faster (higher clearance and shorter half-life) than the S- (active) isomer."( Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
Brennan, JM; Hamilton, TC; Lacreta, FP; O'Dwyer, PJ; Ozols, RF,
)
0.13
"To develop dosing criteria for the use of L-buthionine-S-sulfoximine (active diastereoisomer) as a glutathione depletor in the clinic, using a pharmacodynamic and pharmacokinetic in vitro-in vivo approach."( Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine.
Bump, EA; Coleman, CN; Griffith, OW; Hurwitz, SJ; Lai, LL; Malaker, K; Riese, N, 1994
)
0.29

Compound-Compound Interactions

ExcerptReferenceRelevance
" BSO demonstrated in vivo antitumor activity in B16 melanoma-bearing mice prolonging survival by 29% and in combination with 3,4-DHBA resulted in a slight (48% versus 38%) increase in life span as compared to 3,4-DHBA alone."( Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan.
FitzGerald, GB; Prezioso, JA; Wick, MM, 1992
)
0.28
" SHDAAs, including doxorubicin (DOX), cyclophosphamide (CTX), carmustine (BCNU) and melphalan (L-PAM) were then combined with L-BSO in mice bearing P388, MOPC-315 or colon 38 tumors."( Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Dorr, RT; Soble, MJ,
)
0.13
"The radiosensitizing effects of misonidazole (MISO) in combination with D,L-buthionine-S, R-sulfoximine (BSO), an inhibitor of glutathione (GSH) biosynthesis, were studied in NFSa tumors of C3H/He mice."( Radiosensitizing effect of misonidazole in combination with an inhibitor of glutathione synthesis in murine tumors.
Abe, M; Komuro, C; Nishidai, T; Ono, K; Shibamoto, Y; Takahashi, M; Tsutsui, K, 1986
)
0.27

Bioavailability

ExcerptReferenceRelevance
" The oral bioavailability of BSO, based on plasma BSO levels, was extremely low."( Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice.
Grieshaber, CK; Liao, JT; Page, JG; Smith, AC; Wientjes, MG, 1989
)
0.28
" Access to this methodology has permitted the construction of two new adenylated sulfoximines, which were expected to exhibit similar binding affinity and better bioavailability than the original human ASNS inhibitor."( A critical electrostatic interaction mediates inhibitor recognition by human asparagine synthetase.
Ding, Y; Hiratake, J; Ikeuchi, H; Meyer, ME; Richards, NG, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Tumor GSH levels were decreased with all BSO dosing regimens tested."( The radiation dose-response relationship in a human glioma xenograft and an evaluation of the influence of glutathione depletion by buthionine sulfoximine.
Bigner, DD; Brizel, DM; Friedman, HS; Griffith, OW; Halperin, EC; Honore, G; Sontag, MR, 1992
)
0.28
" Dose-response curves were obtained using cells irradiated in the absence or presence of DEM/BSO, which decreased GSH levels by 90-95%."( Depletion of glutathione after gamma irradiation modifies survival.
Eisert, DR; Freeman, ML; Meredith, MJ; Saunders, EL, 1991
)
0.28
" We successfully employed ESR to detect the formation of the 5,5-dimethyl-1-pyrroline-N-oxide (DMPO)/hemoglobin thiyl free radical adduct in the blood of rats dosed with DMPO and tert-butyl hydroperoxide, cumene hydroperoxide, ethyl hydrogen peroxide, 2-butanone hydroperoxide, 15(S)-hydroperoxy-5,8,11,13-eicosatetraenoic acid, or hydrogen peroxide."( In vivo thiyl free radical formation from hemoglobin following administration of hydroperoxides.
Jordan, SJ; Kennedy, CH; Maples, KR; Mason, RP, 1990
)
0.28
" In addition, the hepatic MT content was increased by the administration of cysteine in a dose-response manner."( On the metallothionein, glutathione and cysteine relationship in rat liver.
Armario, A; Garvey, JS; Hidalgo, J, 1990
)
0.28
" with 250 mg/kg of phorone, a GSH depleting agent and/or 200 mg/kg of buthionine sulfoximine (BSO, an inhibitor of GSH biosynthesis) 4 hours before dosing with 5-FU."( Effects of phorone and/or buthionine sulfoximine on teratogenicity of 5-fluorouracil in mice.
Deguchi, T; Mataki, Y; Naya, M; Takahira, H; Yasuda, M, 1990
)
0.28
"A melphalan-resistant human rhabdomyosarcoma xenograft, TE-671 MR, was established in athymic mice by serial melphalan treatment of the parent xenograft, TE-671, at the 10% lethal dosage (LD10); significant resistance was evident after ten passages of the tumor."( Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
Bigner, DD; Bigner, SH; Colvin, OM; Elion, GB; Friedman, HS; Griffith, OW; Horton, JK; Lilley, E; Rosenberg, MC, 1989
)
0.28
" with TCE in a dosage of 125-1000 mg/kg in sesame oil."( Lipid peroxidation: a possible mechanism of trichloroethylene-induced nephrotoxicity.
Beuter, W; Cojocel, C; Mayer, D; Müller, W, 1989
)
0.28
" These experiments were used to establish a repeated dosing protocol for more prolonged GSH depletion."( The pulmonary effects of buthionine sulfoximine treatment and glutathione depletion in rats.
Cihla, HP; Coursin, DB, 1988
)
0.27
" In the liver of the DL-buthionine-(S,R)-sulfoximine (BSO)-treated rats dosed with m-DCB, both of 2,4- and 3,5-DCPSO2Mes were present at significantly lower concentrations than in non-BSO-treated rats."( Contribution of methylsulfonyl metabolites of m-dichlorobenzene to the heme metabolic enzyme induction by the parent compound in rat liver.
Kato, Y; Kimura, R; Kogure, T; Sato, M, 1988
)
0.27
" Further studies should evaluate different dosing intervals to take advantage of the slower rate of GSH replenishment observed in normal tissues compared to solid tumor cells (Colon 38) in vivo."( Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
Dorr, RT; Soble, MJ,
)
0.13
" Tumor GSH could be maintained at a level 8% of control by daily dosing with BSO for 3 days."( Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
Ono, K; Shrieve, DC, 1987
)
0.27
" After a 4-hr pretreatment with DL-buthionine-SR-sulfoximine (BSO), a specific inhibitor of GSH synthesis, male Sprague-Dawley rats were dosed with radiolabeled DMN (250 micrograms/kg)."( Effect of glutathione modulation using buthionine sulfoximine on DNA methylation by dimethylnitrosamine in the rat.
Jensen, DE; Magee, PN; Tacchi, AM, 1987
)
0.27
" Multiple BSO dosing at 16 h intervals allowed the liver to recover between doses, but the recovery in the kidney, lung and bone marrow was only partial and no recovery was seen in the heart."( Depletion of tumour versus normal tissue glutathione by buthionine sulfoximine.
Allalunis-Turner, MJ; Lee, FY; Siemann, DW, 1987
)
0.27
" Kidneys from hamsters treated with the GSH synthesis inhibitor L-buthionine-(S,R)-sulfoximine at a dosage of 1 mmol/kg body wt for 2 hr had 45% of the NP-SH content as compared with kidneys of saline-treated controls."( Glutathione protection against irreversible binding of diethylstilbestrol in the hamster renal cortex.
Adams, SP; Notides, AC, 1987
)
0.27
" To test whether inhibition of protein synthesis was related to GSH depletion, groups of animals were dosed with the alpha, beta-unsaturated carbonyl phorone (diisopropylidenacetone) or the specific inhibitor of GSH synthesis, buthionine sulfoximine (BSO)."( Effect of diethylmaleate and other glutathione depletors on protein synthesis.
Costa, LG; Murphy, SD, 1986
)
0.27
" Different dosing regimens of BSO were found to potentiate L-PAM toxicity in a manner that depended upon the degree of GSH depletion."( Chemosensitization of L-phenylalanine mustard by the thiol-modulating agent buthionine sulfoximine.
Ahmad, S; Greene, K; Kramer, RA; Vistica, DT, 1987
)
0.27
" A series of human ovarian cancer cell lines have been developed in which dose-response relationships to standard anticancer drugs have been determined, and the patterns of cross-resistance between these drugs and irradiation have been established."( Radiation survival parameters of antineoplastic drug-sensitive and -resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine.
Behrens, BC; Grotzinger, KR; Hamilton, TC; Kinsella, TJ; Louie, KG; McKoy, WM; Ozols, RF; Winker, MA, 1985
)
0.27
" Time-dependent pharmacodynamic models are seen as a powerful means to design dosing regimens and to provide a mathematical platform for mechanistic based models."( Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO.
Brennan, J; Gallo, JM; Halbherr, T; Hamilton, TC; Laub, PB; O'Dwyer, PJ; Ozols, RF, 1995
)
0.29
" Therefore, in a second set of experiments, rat embryos were cultured in serum from rats pretreated with two GSH depleters (phorone and buthionine sulfoximine) and subsequently dosed with PCZ."( Profile of procarbazine-induced embryotoxicity in an embryo hepatocyte co-culture system and after in utero glutathione depletion.
Andrews, JE; Ebron-McCoy, MT; Kavlock, RJ; Nichols, HP, 1995
)
0.29
" A dose-response curve showed that a maximum depletion (86%) of GSH in the mother's liver was produced by the 6 mmol/kg dose of BSO."( The effect of in utero administration of buthionine sulfoximine on rat development.
Contreras, R; Ott, S; Reyes, E; Robinson, B, 1995
)
0.29
"To develop dosing criteria for the use of L-buthionine-S-sulfoximine (active diastereoisomer) as a glutathione depletor in the clinic, using a pharmacodynamic and pharmacokinetic in vitro-in vivo approach."( Pharmacodynamics of prolonged treatment with L,S-buthionine sulfoximine.
Bump, EA; Coleman, CN; Griffith, OW; Hurwitz, SJ; Lai, LL; Malaker, K; Riese, N, 1994
)
0.29
" However, glucose protected the cells from killing induced by milder exposure (1 mumol/10(7) cells) to the oxidant causing a shift in the dose-response curve."( The role of glucose in cellular defences against cytotoxicity of hydrogen peroxide in Chinese hamster ovary cells.
Averill-Bates, DA; Przybytkowski, E, 1994
)
0.29
" At low, therapeutically relevant radiation doses, where 2-nitroimidazoles are less efficient sensitizers, the preincubation effect may be even more important, but thiol depletion still minimizes its impact in this region of the dose-response curve."( Enhanced radiation-sensitivity by preincubation with nitroimidazoles: effect of glutathione depletion.
Koch, CJ; Skov, KA, 1994
)
0.29
" Maximal GSH depletion (40% of baseline values, absolute values 200 to 250 ng/10(6) PBLs) was noted after the sixth BSO dose; extended BSO dosing schedules beyond six total BSO doses did not further deplete GSH."( Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.
Alberti, D; Arzoomanian, RZ; Bailey, HH; Mulcahy, RT; Pomplun, M; Spriggs, DR; Tombes, MB; Tutsch, KD; Wilding, G, 1994
)
0.29
"The formation of paramagnetic chromium in the liver of male mice dosed with K2Cr2O7 (10, 20, and 40 mg Cr/kg) by a single ip injection was investigated by electron spin resonance (ESR) spectrometry."( Formation of paramagnetic chromium in liver of mice treated with dichromate (VI).
Furukawa, Y; Sugiyama, M; Susa, N; Ueno, S, 1995
)
0.29
" We measured plasma concentrations of R- and S-BSO by high-performance liquid chromatography (HPLC) in 22 patients throughout the dosing period."( Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer.
Bookman, MA; Brennan, J; Comis, RL; Gallo, JM; Halbherr, T; Hamilton, TC; Hoffman, J; Kilpatrick, D; LaCreta, FP; O'Dwyer, PJ; Ozols, RF; Young, RC, 1996
)
0.29
" Time course and dose-response experiments with MSO showed significant [3H]glutamate release, which was partially attenuated by AP5."( Methionine sulfoximine shows excitotoxic actions in rat cortical slices.
Bains, JS; Curry, K; Pasqualotto, BA; Shaw, CA, 1999
)
1.75
" At the highest dosage (40 mM) the b-wave was significantly reduced within 2 min of injection."( Inhibition of Müller cell glutamine synthetase rapidly impairs the retinal response to light.
Barnett, NL; Pow, DV; Robinson, SR, 2000
)
0.31
" Seizures in CBA/J strain were induced by MSO at a dosage half that necessary to provoke seizures in C57BL/6J, BALB/c, or Swiss mice."( Serotonergic neurotransmission plays a major role in the action of the glycogenic convulsant methionine sulfoximine.
Cloix, JF; Hevor, TK; Picard, M, 2011
)
0.59
" The dose-response curve of MSO-dependent seizures demonstrated that the MSO-Slow mice were highly insensitive to MSO-dependent seizures compared with MSO-Fast inbred mice that were highly sensitivity."( Phenotypic differences between fast and slow methionine sulfoximine-inbred mice: seizures, anxiety, and glutamine synthetase.
Boissonnet, A; Cloix, JF; Hévor, T, 2012
)
0.64
" The animals were randomized into groups and were administered one of the following treatments: saline, PILO, saline+L-α-aminoadipic acid (L-AAA; one dosage tested), PILO+L-AAA, or PILO+L-methionine sulfoximine (three dosages tested)."( A sub-threshold dose of pilocarpine increases glutamine synthetase in reactive astrocytes and enhances the progression of amygdaloid-kindling epilepsy in rats.
Bai, XY; Chen, XM; Deng, DP; Li, SC; Liu, YX; Pan, XH; Sun, HL; Wang, CH; Wang, CY; Zhang, XL; Zhu, W, 2016
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 6.3.1.2 (glutamate--ammonia ligase) inhibitorAn EC 6.3.* (C-N bond-forming ligase) inhibitor that interferes with the action of glutamate--ammonia ligase (EC 6.3.1.2).
geroprotectorAny compound that supports healthy aging, slows the biological aging process, or extends lifespan.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (7)

ClassDescription
methionine derivativeAn amino acid derivative resulting from reaction of methionine at the amino group or the carboxy group, or from the replacement of any hydrogen of methionine by a heteroatom. The definition normally excludes peptides containing methionine residues.
sulfoximideCompounds having the structure RS(=O)=NR.
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
methionine sulfoximineA non-proteinogenic alpha-amino acid that is the sulfoximine derivative of methionine .
L-methionine derivativeA proteinogenic amino acid derivative resulting from reaction of L-methionine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-methionine by a heteroatom.
non-proteinogenic L-alpha-amino acidAny L-alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
L-alpha-amino acid zwitterionZwitterionic form of an L-alpha-amino acid having an anionic carboxy group and a protonated amino group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
endonuclease IVEscherichia coliPotency19.95260.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.56230.100020.879379.4328AID588453
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency6.72940.035520.977089.1251AID504332
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency16.944123.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency0.00670.006026.168889.1251AID488953
flap endonuclease 1Homo sapiens (human)Potency1.33710.133725.412989.1251AID588795
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID74975Percent inhibition was measured on Sheep Brain Glutamine synthetase (GS) at 0.1 mM concentration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
4-N-hydroxy-L-2,4-diaminobutyric acid. A strong inhibitor of glutamine synthetase.
AID74994Percent inhibition was measured on Soybean Glutamine synthetase (GS) at 0.2 mM concentration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
4-N-hydroxy-L-2,4-diaminobutyric acid. A strong inhibitor of glutamine synthetase.
AID74976Percent inhibition was measured on Sheep Brain Glutamine synthetase (GS) at 0.2 mM concentration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
4-N-hydroxy-L-2,4-diaminobutyric acid. A strong inhibitor of glutamine synthetase.
AID74993Percent inhibition was measured on Soybean Glutamine synthetase (GS) at 0.1 mM concentration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
4-N-hydroxy-L-2,4-diaminobutyric acid. A strong inhibitor of glutamine synthetase.
AID75124Percent inhibition was measured on Soybean Glutamine synthetase (GS) at 0.5 mM concentration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
4-N-hydroxy-L-2,4-diaminobutyric acid. A strong inhibitor of glutamine synthetase.
AID407724Inhibition of Mycobacterium tuberculosis glutamine synthetase at 1 mM in water2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Evaluation of the amino acid binding site of Mycobacterium tuberculosis glutamine synthetase for drug discovery.
AID74977Percent inhibition was measured on Sheep Brain Glutamine synthetase (GS) at 0.5 mM concentration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
4-N-hydroxy-L-2,4-diaminobutyric acid. A strong inhibitor of glutamine synthetase.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID407731Inhibition of Mycobacterium tuberculosis glutamine synthetase by transferase assay2008Bioorganic & medicinal chemistry, May-15, Volume: 16, Issue:10
Evaluation of the amino acid binding site of Mycobacterium tuberculosis glutamine synthetase for drug discovery.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,502)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990644 (42.88)18.7374
1990's649 (43.21)18.2507
2000's99 (6.59)29.6817
2010's91 (6.06)24.3611
2020's19 (1.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.18 (24.57)
Research Supply Index7.34 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index70.32 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (0.39%)5.53%
Trials0 (0.00%)5.53%
Reviews44 (2.86%)6.00%
Reviews0 (0.00%)6.00%
Case Studies2 (0.13%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other1,485 (96.62%)84.16%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]